We recently covered pharmaceutical companies sourcing API (active pharmaceutical ingredients) from low-cost countries and the potential risks that accompany the trend. But I came across a video of Columbia Business School Professor Noel Capon interviewing Merck’s Howard Richman that covers a far different pharma procurement angle - the company’s indirect spend success story.

Richman, Merck’s Executive [...]

[Read more →]

Pharmaceutical companies have historically been top-line focused. Due to a combination of patent law and block-buster drugs, they’ve been in a very strong position from a revenue standpoint (think Claratin, the little purple pill and the little blue pill). The model worked well for quite some time due to high volume, exclusivity and high prices [...]

[Read more →]

SpendMatters blogger and all around industry guru Jason Busch is back with another round of Category Chatter podcasts. In case you’re not familiar with the series, the podcasts feature Jason interviewing various Ariba Category Managers on hot topics of the day. If the area of spend they’re covering is of interest to you, Jason’s probing [...]

[Read more →]